When to Order Imaging for Staging and Follow-up of Ovarian Cancer: ACR Appropriateness Decoded

A 62-year-old female presents with a newly diagnosed ovarian mass, highly suspicious for malignancy based on ultrasound and tumor markers. You are coordinating her care and need to order the correct initial staging studies. The goal is to delineate the full extent of disease to guide surgical and medical management, but the options—CT, MRI, PET/CT—all have different strengths, costs, and radiation profiles. Choosing the most effective and efficient imaging pathway is critical. This guide breaks down the American College of Radiology (ACR) Appropriateness Criteria for staging and follow-up of ovarian cancer, providing clear, evidence-based recommendations to ensure you order the right study for the right clinical scenario.

What Does ACR Staging and Follow-up of Ovarian Cancer Cover?

This ACR guideline provides recommendations for imaging adult patients with known or highly suspected epithelial ovarian cancer. The criteria are organized into four distinct clinical variants that cover the entire disease lifecycle, from initial workup to long-term surveillance. This includes pretreatment staging, posttreatment response evaluation, routine surveillance in asymptomatic patients, and evaluation for suspected recurrence. The primary goal of imaging in these contexts is to accurately assess the extent of disease, including peritoneal carcinomatosis, lymphadenopathy, and distant metastases, which are crucial for determining treatment strategy (e.g., primary debulking surgery versus neoadjuvant chemotherapy).

These guidelines do not cover the initial evaluation of an undifferentiated adnexal mass, for which ultrasound is the primary modality. They also do not specifically address non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord-stromal tumors), although the imaging principles may be similar. The focus is on providing a standardized, evidence-based approach for clinicians managing patients after the initial diagnosis of ovarian cancer is established.

What Imaging Should I Order for Staging and Follow-up of Ovarian Cancer? Recommendations by Clinical Scenario

The optimal imaging strategy for ovarian cancer depends entirely on the clinical context. The ACR provides specific ratings for each scenario to guide ordering physicians.

For pretreatment staging of a newly diagnosed ovarian cancer, the ACR rates CT of the abdomen and pelvis with IV contrast and CT of the chest with IV contrast as Usually appropriate. This combination is the workhorse for initial staging, providing a comprehensive assessment of the primary tumor, peritoneal and omental disease, nodal status, and distant metastases. MRI of the abdomen and pelvis may be appropriate as a problem-solving tool for characterizing the primary adnexal mass or in patients with a contrast allergy. FDG-PET/CT is also rated as may be appropriate but is not typically the first-line modality for initial staging.

For posttreatment response evaluation and for evaluating a suspected or known recurrence (e.g., due to rising CA-125 levels or new symptoms), the recommendations are similar. CT of the abdomen/pelvis and chest with IV contrast remains Usually appropriate. In these scenarios, FDG-PET/CT is also considered Usually appropriate, as it can be highly sensitive for detecting recurrent disease, especially when CT findings are equivocal. MRI remains a “May be appropriate” option for problem-solving in the pelvis.

In contrast, for posttreatment routine surveillance in an asymptomatic patient with no suspected recurrence, no imaging modality is rated as “Usually appropriate.” The ACR panel rates CT and MRI of the abdomen and pelvis, with or without contrast, as May be appropriate. This reflects the ongoing debate about the utility and timing of routine surveillance imaging in asymptomatic patients. The decision to perform imaging in this setting often depends on institutional protocols and individual patient factors. Ultrasound is considered “Usually not appropriate” for all staging and follow-up scenarios due to its limited ability to detect extra-ovarian disease.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Ovarian Cancer Imaging: Radiation Dose Tradeoffs

While ovarian cancer is predominantly a disease of adults, it can occur in pediatric and adolescent patients, most commonly as germ cell tumors. The ACR guidelines for this topic provide distinct relative radiation level (RRL) estimates for adult and pediatric populations, reflecting the critical importance of the ALARA (As Low As Reasonably Achievable) principle in younger patients. For instance, a CT of the abdomen and pelvis is rated as RRL ☢ ☢ ☢ (1-10 mSv) for adults but carries a higher RRL category of ☢ ☢ ☢ ☢ (3-10 mSv) for children. This higher categorization for the same dose range underscores the increased lifetime attributable risk of radiation-induced malignancy in pediatric patients, whose developing tissues are more radiosensitive and who have a longer lifespan over which potential harm could manifest.

This distinction emphasizes that while CT is often necessary for accurate staging, clinicians should be particularly judicious when ordering ionizing radiation-based studies in younger patients. Non-radiation modalities like MRI, rated RRL O (0 mSv), may be considered more strongly as an alternative or for problem-solving in this population when clinically appropriate, balancing diagnostic yield against the long-term risks of cumulative radiation exposure.

Imaging Protocol Details for Staging and Follow-up of Ovarian Cancer

Once you’ve decided on the right study based on the clinical scenario, ensuring it is performed correctly is the next critical step. The specific imaging protocol—including contrast timing, slice thickness, and reconstruction parameters—directly impacts diagnostic quality. Our protocol guides provide detailed, practical information for the key studies recommended in these ACR criteria.

• CT Chest/Abdomen/Pelvis with IV Contrast
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines and radiation safety can be complex. GigHz offers a suite of free, straightforward tools designed to support clinical decision-making at the point of care.

For scenarios beyond ovarian cancer, the Imaging Appropriateness Selector provides a fast way to search the complete, unabridged ACR guidelines for thousands of clinical presentations. It helps you find the evidence-based recommendation for your specific patient situation in seconds.

To ensure the study you order is technically optimized for the clinical question, the Imaging Protocol Library offers detailed, scannable protocols for hundreds of common and advanced CT and MRI examinations. This resource is valuable for trainees and ordering providers who want to understand the specifics of how a study is performed.

Communicating radiation risk is a key part of informed consent. The Radiation Dose Calculator helps you estimate effective dose for various studies and provides simple, intuitive comparisons (e.g., “equivalent to X years of background radiation”) to facilitate conversations with patients about the benefits and risks of necessary imaging.

Frequently Asked Questions about Imaging for Ovarian Cancer

Here are answers to common questions that arise when ordering imaging for the staging and follow-up of ovarian cancer.

Why is CT the primary modality for initial staging of ovarian cancer?

Contrast-enhanced CT of the chest, abdomen, and pelvis is considered the workhorse for initial staging because it is fast, widely available, and provides excellent comprehensive evaluation of the disease. It is highly effective at detecting the key features that determine stage and surgical approach, including the size of the primary tumor, peritoneal and omental implants, serosal disease on the liver and spleen, ascites, lymphadenopathy, and distant metastases to the lungs or liver.

What is the specific role of FDG-PET/CT in ovarian cancer?

While FDG-PET/CT is only “May be appropriate” for initial staging, its role becomes more prominent in the post-treatment setting. It is rated “Usually appropriate” for assessing treatment response and for evaluating suspected recurrence, particularly when a patient’s CA-125 level is rising but conventional CT imaging is negative or equivocal. The metabolic information from PET can detect small-volume recurrent disease that may not be visible on anatomic imaging alone, helping to guide further treatment or cytoreductive surgery.

Ultrasound is used for initial diagnosis. Why is it ‘Usually not appropriate’ for staging and follow-up?

Transvaginal and transabdominal ultrasound are essential for the initial detection and characterization of a suspicious adnexal mass. However, for staging and surveillance, the goal shifts to assessing disease spread throughout the abdomen and pelvis. Ultrasound has significant limitations in this role; it cannot reliably visualize small peritoneal implants, evaluate retroperitoneal lymph nodes, or screen for distant metastases. Therefore, once cancer is diagnosed, cross-sectional imaging like CT is required for a complete assessment.

When should I consider MRI instead of CT for ovarian cancer follow-up?

MRI is rated “May be appropriate” and serves as an excellent problem-solving tool. It can be particularly useful for clarifying indeterminate findings in the pelvis seen on a prior CT, such as distinguishing post-surgical changes from recurrent tumor. MRI also offers superior soft tissue contrast without using ionizing radiation, making it a valuable option for younger patients who may require numerous follow-up scans or for patients with a severe allergy to iodinated CT contrast agents.

Is a non-contrast CT ever sufficient for surveillance?

A non-contrast CT is rated as “May be appropriate” for routine surveillance but is generally less sensitive than a contrast-enhanced study. IV contrast is crucial for highlighting peritoneal implants, defining the extent of soft tissue masses, and evaluating lymph nodes and organ involvement. A non-contrast study might be considered in a patient with a severe contrast allergy or significant renal impairment where a contrast-enhanced study is contraindicated, but its diagnostic utility for detecting subtle recurrence is lower.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026